COMMUNIQUÉS West-GlobeNewswire

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
15/04/2025
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi , CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global [...]
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
15/04/2025
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a [...]
How to Lower Blood Sugar Naturally: A Comprehensive Review of GlucoRedi, the Best Diabetes Supplement
15/04/2025
Nampa, April 15, 2025 (GLOBE NEWSWIRE) -- How to Lower Blood Sugar Naturally: A Comprehensive Review of GlucoRedi, the Best Diabetes Supplement Glucoredi diabetes control supplement Content promoted through the Branding [...]
Concept Life Sciences expands expertise with key appointments to Scientific Advisory Board and investments to strengthen integrated drug discovery capabilities
15/04/2025
- Appointments come as the business invests a six-figure sum into advanced technology and systems - CHAPEL-EN-LE-FRITH, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences (CLS), a leading [...]
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
15/04/2025
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
15/04/2025
ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded
15/04/2025
ORION CORPORATION PRESS RELEASE 15 April 2025 at 10.00 EEST Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded Orion Corporation announced in a press release on 10 March 2025 that the [...]
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
15/04/2025
MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales [...]
Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
15/04/2025
April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S [...]
Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
15/04/2025
April 15, 2025 Announcement no. 11 Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S Copenhagen, Denmark, April 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S [...]
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
15/04/2025
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in- [...]
CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions
15/04/2025
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS [...]
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
15/04/2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through [...]
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
15/04/2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs [...]
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
15/04/2025
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting [...]
Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO
15/04/2025
Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’ [...]
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
15/04/2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”
15/04/2025
Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and [...]
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
15/04/2025
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Pages